For people living with a complex lymphatic anomaly (CLA), getting clear answers can be difficult.
The lymphatic system reaches throughout the body, yet it can be hard to see with standard medical imaging. That can make it challenging for clinicians to understand how a condition is affecting a patient, how severe it is, and whether a treatment is working.
Researchers at UT Southwestern Medical Center and The University of Texas at Arlington are working to change that. In a recent presentation for the Research Network, they described both the imaging tools used today and an experimental PET imaging method that may one day provide a more detailed and measurable view of lymphatic flow.
The technology is still being studied in mice. It is not yet available for patient care. Even so, the findings point toward a future in which clinicians may be able to see the lymphatic system more clearly and better understand how it is functioning.
What Are Complex Lymphatic Anomalies?
CLAs are rare conditions involving abnormal lymphatic vessels. They may affect more than one part of the body and can interfere with normal lymphatic flow.
These conditions can involve the bones, lungs, spleen, soft tissues, digestive system, or major lymphatic vessels in the chest and abdomen.
Several different conditions fall under the CLA category:
- Generalized lymphatic anomaly can affect several organs, including the lungs, spleen, and bones.
- Kaposiform lymphangiomatosis is often more aggressive and may cause bleeding, abnormal tissue growth, and fluid collections.
- Gorham-Stout disease, sometimes called vanishing bone disease, can cause progressive loss of bone and increase the risk of fractures.
- Central conducting lymphatic anomaly affects major vessels that carry lymph through the center of the body.
- Generalized lymphatic dysplasia is linked to inherited genetic changes and may cause widespread swelling and organ involvement.
These conditions can overlap. A patient may not fit neatly into only one category.
That is one reason diagnosis and care often require a multidisciplinary team that includes radiologists, vascular anomaly specialists, surgeons, geneticists, and other clinicians.
Why Is Lymphatic Imaging So Difficult?
The lymphatic system presents several challenges for medical imaging.
Lymphatic vessels are much smaller than major blood vessels. Unlike blood, lymph does not travel in a circle. It moves in one direction through a network of vessels and lymph nodes before returning to the bloodstream.
A contrast agent injected into a vein will not automatically fill the entire lymphatic system. To see specific lymphatic pathways, clinicians may need to inject contrast into lymph nodes or nearby tissues.
The system also extends across nearly the entire body. An imaging test may need to cover a large area while still showing very small structures.
Current tools can provide important information, but each has limitations.
How Are Complex Lymphatic Anomalies Imaged Today?
Ultrasound may be used first when a patient has a swelling or soft-tissue mass. It can identify fluid-filled spaces, but it only shows a limited area at one time.
X-rays are useful for finding bone damage and fractures.
CT scans can show changes in the lungs, fluid collections, and abnormalities in organs or tissues.
MRI is often the main imaging tool for complex lymphatic anomalies. It can show fluid, bone involvement, soft-tissue changes, and abnormalities across several organs.
A specialized MRI test called dynamic contrast-enhanced MR lymphangiography can also show the direction of lymphatic flow. Clinicians may use it to find a leak, identify abnormal backward flow, and plan procedures such as embolization.
These tests help clinicians understand the anatomy of a patient’s condition. However, researchers still need better ways to measure lymphatic function and disease severity.
The Search for a More Precise Imaging Tool
Researchers are exploring positron emission tomography, better known as PET imaging.
PET is already widely used in cancer care, brain imaging, and heart medicine. It can detect very small amounts of a radioactive imaging agent and can provide measurable information about activity inside the body.
However, existing PET agents usually enter the bloodstream. Very little reaches the lymphatic system, which makes them poorly suited for lymphatic imaging.
To address this problem, the researchers developed very small particles designed to enter lymphatic vessels while largely avoiding direct entry into the bloodstream.
The particles are coated with polyethylene glycol, or PEG, a material already used in several medical products. The experimental particles also contain copper and selenium.
Their size is an important part of the design. They are intended to be small enough to enter lymphatic vessels but large enough to avoid immediately passing into blood vessels.
What Were the Key Findings?
The researchers first tested the PET imaging particles in healthy mice.
After the particles were injected, PET imaging followed them as they moved through a series of lymph nodes and central lymphatic pathways.
The images showed several encouraging results.
PET could show lymphatic drainage routes
The particles traveled from the injection site through expected lymphatic pathways. In some experiments, the researchers could see both lymph nodes and the vessels connecting them.
Particle size affected how the material moved
Smaller particles moved through the lymphatic system more quickly. Larger particles moved more slowly and appeared to remain in certain lymphatic areas for longer periods.
This finding may help researchers adjust the size of future imaging agents depending on what they want to examine.
The images suggested a pulsing pattern inside lymph nodes
Some lymph nodes appeared to show repeating rises and falls in activity.
The researchers believe this may represent pulses of lymph moving through the nodes. Similar behavior had been predicted in mathematical studies, but the research team described this as a possible first direct observation of the pattern in a living animal using PET.
More research is needed to confirm exactly what the pattern represents.
PET detected differences in mice with lymphedema
The researchers also tested the imaging method in mice with a genetically caused form of primary lymphedema.
The affected mice showed a different drainage pattern than healthy mice. Some expected lymph nodes did not appear, while other lymph nodes became more active.
The researchers suggested that these alternate pathways may represent the body trying to compensate for impaired lymphatic drainage.
Early safety testing was encouraging, but incomplete
The particles gradually broke down and were mainly found in the liver before leaving the body.
At the standard imaging dose, the researchers did not report clear evidence of major liver or kidney injury in the tests presented. At five times the imaging dose, however, one laboratory measurement changed significantly, possibly because of excess copper.
The team emphasized that safety must be studied carefully before the technology can be considered for humans.
Questions remain about inflammation, how the particles behave in different organs, and whether they could pose added risks for people with disorders of copper metabolism.
What Could This Mean for Patients?
This research does not yet change patient care.
The new PET agents have only been studied in animals, and they will require more laboratory testing before human trials could be considered.
Still, the work addresses a major need.
A future lymphatic-specific PET scan might help clinicians:
- See small lymphatic vessels more clearly
- Follow the direction and speed of lymph flow
- Identify abnormal or alternate drainage pathways
- Measure changes in lymphatic function
- Compare disease activity before and after treatment
- Plan procedures with more precise information
For patients, better imaging could eventually mean fewer unanswered questions and a clearer picture of what is happening inside the body.
It could also help clinicians move beyond describing where abnormalities are located. They may be able to measure how well the lymphatic system is working.
What Does This Mean for Scientists and Clinicians?
The findings suggest that PET could become a valuable research tool for studying lymphatic biology.
Scientists may be able to use this approach to observe how lymph moves, how lymph nodes respond to disease, and how the body creates alternate drainage routes.
The technology could also support the development of new treatments. Researchers may be able to test whether a therapy improves lymphatic flow and quantify that improvement over time.
Several questions still need answers:
- What is the best particle size for human lymphatic imaging?
- Where should the imaging agent be injected?
- How long would it take to reach the central lymphatic system in a person?
- Could the particles cause inflammation or collect in certain tissues?
- How would the agent behave in people with liver, kidney, or copper-processing disorders?
- Can the process be made safe, practical, and consistent?
Answering these questions will require collaboration among patients, clinicians, imaging specialists, chemists, engineers, and regulatory experts.
A Step Toward Greater Clarity
People affected by isolated lymphatic malformations and complex lymphatic anomalies often face years of uncertainty. They may undergo many scans while still lacking a complete explanation of how their lymphatic system is functioning.
This research will not remove that uncertainty overnight.
But it represents meaningful progress toward a more precise way of seeing the lymphatic system.
Today, MRI remains the primary imaging tool for complex lymphatic anomalies. In the future, lymphatic-specific PET imaging may be able to add something different: a measurable view of lymph movement in real time.
That possibility is still being tested. It must be approached with care, strong safety research, and honest communication.
For patients and families searching for answers, the most important message is not that a new scan is ready. It is that researchers are working to make an often-invisible system easier to see, understand, and treat.
Because rare should never mean invisible. And no one should have to navigate a lymphatic condition alone.
